|
KMID : 0378019950380040117
|
|
New Medical Journal
1995 Volume.38 No. 4 p.117 ~ p.122
|
|
|
A Clinical Study on Therapeutic Effects of Isepacin in Patients with Acute Pyelonephritis
|
|
|
|
|
Abstract
|
|
|
Isepacin is a new aminoglycoside derivative which was recently developed by Shering-Plough and Tokyo Jozo Co. This aminoglycoside-derivative is known as broad spectrum antibacterial activity about Gram negative and postive micro-organisms and it has lower nehprotoxicity and ototoxicity than other aminoglycosides.
In order to evaluate the therapeutic effect and safety of Isepacin for the patients with acute pyelonephritis, twenty patients with acute pyelonephritis who were admitted in Chungnam National University Hospital from June 1994 to February 1995 were included in this study. Sixteen patients(80%) with acute pyelonephritis recovered completely with average 8.2 day courses of Isepacin*(200mg twice/day) alone. Four patients(20%) showing prolonged fever and suspicion of renal abscess had to be treated with addition of cephalosporin derivative and other antibiotics. These four patients showed underlying diseases such as diabetes, obstructive uropathy or chronic renal failure. After Isepacin treatment, CBC, blood chemistry and renal function in patients with average 8.2 day course of Isepacin treatment did not show change significantly. In conclusion, we think that Isepacin treatment is recommended as an effective and safe aminoglycoside antibiotics in patients with uncomplicated upper urinary tract infection.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|